Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same author

Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study.

Annals of medicine and surgery (2012)·2026
Same author

Pre-emptive <i>DPYD</i> genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patients.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets.

ANZ journal of surgery·2026
Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: May 21, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Linda Mileshkin1, Bhaumik Shah, Michael Michael

  • 1Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia.

Chemotherapy Research and Practice
|June 6, 2012
PubMed
Summary

Personalized cancer treatment is advancing due to new molecular targets like epidermal growth factor receptor (EGFR) and K-ras. Challenges in implementing these tumor tests include tissue quality, access, and interpretation consensus.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 21, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Biology

Background:

  • Recent advances in tumor biology enable personalized treatment strategies for specific cancers.
  • Molecular targets such as epidermal growth factor receptor (EGFR) and K-ras are crucial for tumor classification and guiding therapy.
  • Clinical implementation of novel molecular tests faces several practical challenges.

Purpose of the Study:

  • To review the challenges associated with implementing molecular tests for tumor characterization in clinical practice.
  • To discuss the specific examples of epidermal growth factor receptor (EGFR) and K-ras testing.
  • To propose actionable solutions for overcoming identified barriers.

Main Methods:

  • Review of current literature and clinical practice guidelines.
  • Detailed examination of two key molecular targets: EGFR and K-ras.
  • Analysis of potential obstacles including tissue specimen quality, test accessibility, interpretation consensus, and funding.

Main Results:

  • Molecular profiling of tumors using targets like EGFR and K-ras is essential for personalized medicine.
  • Significant barriers exist in the routine clinical application of these tests.
  • These barriers include logistical, technical, and financial aspects.

Conclusions:

  • Addressing challenges in tissue quality, test availability, and interpretation is critical for successful implementation of molecular diagnostics.
  • Standardization and clear guidelines are needed to facilitate the integration of these tests into routine cancer care.
  • Proactive strategies are required to overcome obstacles and fully realize the potential of personalized cancer therapy.